X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DR. REDDYS LAB - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DR. REDDYS LAB ABBOTT INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 36.5 28.3 129.3% View Chart
P/BV x 9.4 3.5 269.9% View Chart
Dividend Yield % 0.7 0.8 97.0%  

Financials

 ABBOTT INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
DR. REDDYS LAB
Mar-18
ABBOTT INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6,1102,788 219.2%   
Low Rs3,9961,902 210.1%   
Sales per share (Unadj.) Rs1,552.2860.8 180.3%  
Earnings per share (Unadj.) Rs188.857.1 330.8%  
Cash flow per share (Unadj.) Rs196.4122.0 161.0%  
Dividends per share (Unadj.) Rs55.0020.00 275.0%  
Dividend yield (eoy) %1.10.9 127.6%  
Book value per share (Unadj.) Rs796.6757.7 105.1%  
Shares outstanding (eoy) m21.25165.91 12.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.32.7 119.5%   
Avg P/E ratio x26.841.1 65.1%  
P/CF ratio (eoy) x25.719.2 133.8%  
Price / Book Value ratio x6.33.1 205.0%  
Dividend payout %29.135.0 83.1%   
Avg Mkt Cap Rs m107,376389,034 27.6%   
No. of employees `0003.323.5 14.1%   
Total wages/salary Rs m3,93732,149 12.2%   
Avg. sales/employee Rs Th9,929.36,070.8 163.6%   
Avg. wages/employee Rs Th1,185.11,366.6 86.7%   
Avg. net profit/employee Rs Th1,207.7402.5 300.1%   
INCOME DATA
Net Sales Rs m32,985142,810 23.1%  
Other income Rs m1,1701,552 75.4%   
Total revenues Rs m34,155144,362 23.7%   
Gross profit Rs m5,24523,512 22.3%  
Depreciation Rs m16210,772 1.5%   
Interest Rs m38788 4.8%   
Profit before tax Rs m6,21513,504 46.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2034,380 50.3%   
Profit after tax Rs m4,0129,468 42.4%  
Gross profit margin %15.916.5 96.6%  
Effective tax rate %35.432.4 109.3%   
Net profit margin %12.26.6 183.5%  
BALANCE SHEET DATA
Current assets Rs m22,655104,984 21.6%   
Current liabilities Rs m6,68168,938 9.7%   
Net working cap to sales %48.425.2 191.9%  
Current ratio x3.41.5 222.7%  
Inventory Days Days6574 87.1%  
Debtors Days Days29104 28.1%  
Net fixed assets Rs m835104,385 0.8%   
Share capital Rs m213830 25.6%   
"Free" reserves Rs m16,715124,886 13.4%   
Net worth Rs m16,928125,716 13.5%   
Long term debt Rs m025,089 0.0%   
Total assets Rs m24,162225,443 10.7%  
Interest coverage x163.718.1 902.5%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.40.6 215.5%   
Return on assets %16.84.5 368.5%  
Return on equity %23.77.5 314.7%  
Return on capital %36.99.7 380.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36972,623 0.5%   
Fx outflow Rs m3,80718,916 20.1%   
Net fx Rs m-3,43853,707 -6.4%   
CASH FLOW
From Operations Rs m1,52718,030 8.5%  
From Investments Rs m-2,148-14,883 14.4%  
From Financial Activity Rs m-1,024-4,440 23.1%  
Net Cashflow Rs m-1,646-1,236 133.1%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.4 146.3%  
FIIs % 0.1 35.3 0.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.1 15.3 111.8%  
Shareholders   18,270 75,885 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SANOFI INDIA  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Lower; Infosys & Yes Bank Top Losers(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading mixed with stocks in the capital goods sector and metal sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 18, 2018 03:35 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS